Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Arshvidya After School Program on Cognitive Processes in Elementary School Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03813888
Recruitment Status : Completed
First Posted : January 23, 2019
Last Update Posted : January 23, 2019
Sponsor:
Collaborators:
Warwick Research Services
Arsha Vidya Study Centre, Tamilnadu, India
Information provided by (Responsible Party):
NMP Medical Research Institute

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The impact of Arsha Vidya program on cognitive performance was examined in elementary school children. The study compares the effects of arsha vidya after school routine with usual after school routine in healthy 8-11 year-old Indian children.

The main objective of the study is to investigate the effect on cognitive function, behaviour and emotions.


Condition or disease Intervention/treatment Phase
Cognitive Change Other: Arsha Vidya chldren's Group Other: Usual Activity group Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Effect of Arshvidya After School Program on Cognitive Processes in Elementary School Children
Actual Study Start Date : March 21, 2017
Actual Primary Completion Date : January 15, 2018
Actual Study Completion Date : March 12, 2018
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arsha Vidya Group
After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
 Other: Arsha Vidya chldren's Group
Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
Usual Activity Group
After school, control group were asked to conitue their usual routine.
 Other: Usual Activity group
Usual after school activities at home.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cognitive function [ Time Frame: Change from baseline to 12-week ]
    Cognitive functions measured by the Cambridge Neuropsychological Test Automated Battery


Secondary Outcome Measures :
  1. Behaviour [ Time Frame: Change from Baseline to 12-weeks ]
    Behaviour measured by the Behavior Rating Inventory of Executive Function

  2. Attention [ Time Frame: Change from baseline to 12-weeks ]
    Attention measured by the D2 Test of Attention


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be 8 - 11 years of age at the start of the intervention
  • Healthy Children
  • Not start new activity within the intervention period
  • Parental conset
  • Parents to allow and participate where needed in intervention

Exclusion Criteria:

  • Serious chronic illnesses and diseases
  • Diagnosed with any psychiatric illness
  • Intake of medication that may affect study outcomes
  • not able to continue for 12-weeks of participation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03813888


Locations
Layout table for location information
India
NMP Medical Research Institue
Jaipur, Rajasthan, India, 302019
Sponsors and Collaborators
NMP Medical Research Institute
Warwick Research Services
Arsha Vidya Study Centre, Tamilnadu, India
Investigators
Layout table for investigator information
Principal Investigator: Neha Sharma, PhD Warwick Research Services
Study Director: Puneet Sharma Sarvatra International, Dubai
Study Chair: Buddhatmananda Saraswati Arsha Vidya Study Centre, India
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: NMP Medical Research Institute
ClinicalTrials.gov Identifier: NCT03813888    
Other Study ID Numbers: NMP/ Arsha/0092
First Posted: January 23, 2019    Key Record Dates
Last Update Posted: January 23, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No